Ameet Nathwani
Chief Executive Officer
Biomolecular condensates have reshaped our fundamental understanding of cell biology. When condensates are dysregulated, normal networks fail, driving complex disease.
Dewpoint turns this insight into breakthrough medicines. Our award-winning, integrated platform maps, measures, and modulates condensates to reveal causal mechanisms. It pinpoints unique ‘druggable’ nodes or makes conventionally ‘undruggable' targets accessible. Our end-to-end discovery engine unites high-resolution biology, chemistry, proprietary datasets, and AI to move from novel target to drug candidate with speed and precision.
As recognized leaders in condensate science, we are creating a new class of therapies - condensate modulators - for patients where current approaches are not enough.
We are Dewpoint Therapeutics.
At Dewpoint, we’re not only leading a revolution in drug discovery, we’re re-defining the very spirit of what company culture can be. Together we’ve built a unique place to work. Our teams feel inspired, valued and included, and Dewpoint is a place where you can show up as your authentic self to impact science, patients and the future of medicine.
For every role, we hire based on talent, aptitude and an eagerness to learn and grow.
We have the experience to help the right person further develop capabilities and thrive to their full potential.
So if you don’t see a perfect opportunity, but you’re still interested in being part of the D.team, please get in touch.
One evening in the late fall of 2018, Tony Hyman was at his home in Dresden, talking by speakerphone with his new startup co-founder Rick Young back in Cambridge. “Rick and I were discussing how to name the company,” Hyman remembers. “I was walking around the room, and we were coming up with one terrible name after another. ‘Phase Space’ was something I was keen on, and Rick was like, ‘That’s terrible, Tony.’ And then Suzanne came out of the kitchen and said, ‘Why don’t you call it Dewpoint?’”
Hyman and his wife Suzanne Eaton met in California when Hyman was a postdoc, then continued together to Heidelberg, where they both conducted research in cell biology, ultimately moving to Dresden to start the Max Plank Institute of Molecular Cell Biology and Genetics.
In addition to being a leading scientific voice at MPI, Eaton was a Renaissance woman—an accomplished writer, chef, concert pianist, mother, and martial-arts practitioner who was also beloved by the MPI-CBG staff as a thoughtful and infinitely attentive listener and advisor. “She was the best of America in that way,” Hyman says. “She had a real mastery of language and words, a precision – and coming up with our name ‘Dewpoint’ represented that ability to think about language properly.”
With a touch of imagination, our name evokes the moment of phase separation inside cells, when intrinsically disordered proteins and other biomolecules form condensates.
The discovery of biomolecular condensates sparked an entirely new understanding of biology and the way we think about the origin and treatment of diseases. Dewpoint is advancing these learnings to identify new targets and mechanisms of action across multiple biological pathways to develop new therapies.
Dewpoint has developed the ability to tackle the root cause of complex diseases and address previously undruggable targets.
Our ERSAi technology explores and codifies relationships between condensates, human disease and chemistry to accelerate discovery of next generation medicine.
In 2022, we were granted two groundbreaking foundational technology patents, cementing our leadership in condensate drug discovery.
Dewpoint is a team of the world’s greatest condensate thought leaders and drug hunters - including our pioneering scientific founders, Tony Hyman and Rick Young, a world-class Scientific Advisory Board led by Nobel Laureate Phil Sharp, and a highly-experienced global leadership team and D. team nearly 100 strong.
Since our founding, we have forged discovery partnerships with leading global pharmaceutical companies across broad therapeutic areas.
Together with our proprietary programs, these collaborations expanded our pipeline and are accelerating our path towards clinical candidates.
With funding from leading tech and biotech investors, we secured a strong financial runway to progress our condensate discovery programs.
In 2022 we strengthened our financial position with a successful Series C raise for $150 million.
Founding investor Polaris Partners led the equity round, joined by Samsara BioCapital, 6 Dimensions Capital, EcoR1 Capital, Alexandria Venture Investments, and Leaps by Bayer.
Round led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors.
Round led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Bioventures, Mirae Asset Capital, and NS Investment. Also joining the round were existing investors Leaps by Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures.
Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science
